Biocon has received marketing authorization from European Commission (EC) for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). The company’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach. This step follows its positive CHMP opinion on September 17, 2026.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.